Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant ...

In September 2025, the Company launched AboutNAD®, a next-generation digital platform designed to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging.

Harvard Bioscience, Inc. will release its financial results for the fourth quarter of 2024 on March 12, 2025, before the market opens, and will host a conference call at 8:00 a.m. Eastern Time to ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript March 12, 2025 Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $0.06, expectations were $0.05. Operator: ...

Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its financial results for the first quarter of 2025 on May 12, 2025, before the market opens, followed by a conference call at 8:00 a.m. Eastern ...

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company has appointed Jeff ...

Octave Bioscience, Inc. is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson’s ...

“We delivered an excellent second quarter, with $31.1 million in net sales, up 37% year-over-year, and $3.6 million in net income,” said Niagen Bioscience CEO Rob Fried. “As the pioneers of this ...

Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 ...

Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.025. Operator: Good day, and welcome to the Second Quarter 2025 Harvard Bioscience Earnings ...

Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.55. Operator: Welcome to the conference call hosted by Daré Bioscience Therapeutics Company’s Second ...